The OMERACT 6 Minimal Clinically Important Difference/Low Disease Activity Workshop was organized with the aim of meeting the many challenges that exist in determining a low disease activity in rheumatoid arthritis (RA). This article presents an overview of that workshop, including results of the voting, a summary of associated discussions, recommendations, and a proposed research agenda.
|Number of pages||4|
|Journal||Journal of Rheumatology|
|Publication status||Published - 1 May 2003|
- Disease activity
- Outcome and process assessment
- Rheumatoid arthritis